ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.330
-0.010 (-0.43%)
At close: Aug 28, 2025, 4:00 PM
2.340
+0.010 (0.43%)
After-hours: Aug 28, 2025, 7:57 PM EDT

Company Description

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.

Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.

Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

ImmunityBio, Inc.
ImmunityBio logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees680
CEORichard Adcock

Contact Details

Address:
3530 John Hopkins Court
San Diego, California 92121
United States
Phone844 696 5235
Websiteimmunitybio.com

Stock Details

Ticker SymbolIBRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001326110
CUSIP Number45256X103
ISIN NumberUS45256X1037
Employer ID43-1979754
SIC Code2836

Key Executives

NamePosition
Richard Gerald AdcockPresident, Chief Executive Officer and Director
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.Sc.Executive Chairman of the Board and Global Chief Scientific and Medical Officer
David C. SachsChief Financial Officer
Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer and Director
Regan J. LauerChief Accounting Officer
Dr. Enrique Diloné Ph.D., RACChief Technology Officer
Jason R. Liljestrom J.D.General Counsel and Corporate Secretary
Sarah SingletonChief Communications Officer and Head of Patient Advocacy
Dr. Leonard S. Sender M.D.Chief Medical Officer of Liquid Tumors and Cell Therapy
Dr. Sandeep K. Reddy M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Aug 8, 20258-KCurrent Report
Aug 5, 202510-QQuarterly Report
Aug 5, 20258-KCurrent Report
Jul 28, 2025424B5Filing
Jul 25, 20258-KCurrent Report
Jun 23, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 20, 20258-KCurrent Report
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
May 5, 20258-KCurrent Report